May #81 : Fast Lane T Cells

POZ - Health, Life and HIV
Subscribe to:
POZ magazine
Join POZ: Facebook MySpace Twitter Pinterest
Tumblr Google+ Flickr MySpace
POZ Personals
Sign In / Join

Back to home » Archives » POZ Magazine issues

Table of Contents

Divinely Driven Dick

The Doctor Is Out

Say Aaaaah!



Loan Ranger

Raging Bull

Global Yodel

Bush 2, MaryJane 0


Afghan AIDS

Hemo Hero

Georgia on My Mind

I Want My HIV TV

Jock Sock


Spin Cycle

Seattle Rattle

Prime Time

Rhesus in Pieces

Fast Lane T Cells

Sustiva Diva

Coke Is It


Marathon Man

Love Handles

Publisher's Letter


Playing (for Keeps) in Poughkeepsie



Most Popular Lessons

The HIV Life Cycle


Herpes Simplex Virus

Syphilis & Neurosyphilis

Treatments for Opportunistic Infections (OIs)

What is AIDS & HIV?

Hepatitis & HIV

email print

May 2002

Fast Lane T Cells

Could solving the prickly mystery of how CD4 cells are lost lead to new approaches to therapy? Re

Could solving the prickly mystery of how CD4 cells are lost lead to new approaches to therapy? Researchers think so, and here's why. The long-held theory that HIV depletes its primary target, CD4 cells, by blocking new T-cell production was dealt a blow -- make that a one-two punch -- by a duo of recent studies that reached a new conclusion: The virus actually accelerates the division (proliferation) of existing T cells (both CD4s and CD8s) and increases their rate of death. So the eventual loss of CD4 cells that brings on immune deficiency and disease results from increased cell death, rather than decreased cell production.

These breakthrough findings were reported independently in December's Journal of Experimental Medicine by two top teams -- one led by virologist Joseph Kovacs, MD, at the National Institute of Allergy and Infectious Diseases (NIAID) and the other by Hiroshi Mori, MD, and David Ho, MD, both of the Aaron Diamond AIDS Research Center. More specifically, the Kovacs team found that HIV is causing a very rapid expansion of one subset of CD4 cells, while there is a much slower increase in a different subset. The cells in the fast-building group also die at a much quicker rate than the ones in the slow group. Interestingly, viral loads only seem to correlate with the size of the rapid proliferator group, not the slowbies. And alas, the current drugs only target the speedsters.

That means that even HAART-takers with nondetectable viral loads may still experience a decline in CD4 cells over time because of what's happening to the untouched slow group. However, if drugs could be developed to target those more slowly proliferating cells, that might help put the brakes on immune decline. For Ho, a "hit early and hit hard" advocate, the discovery supports aggressive treatment to blunt T-cell loss as soon as possible. He cautions that individuals still need to weigh the benefits and risks of HAART, but says, "If we are draining [CD4 cells] from a finite source while allowing HIV replication to occur, there is wear and tear on the immune system. I'd rather preserve the immune system than repair it -- because there are no tools to repair it right now."

[Go to top]

Facebook Twitter Google+ MySpace YouTube Tumblr Flickr Instagram
Quick Links
Current Issue

HIV Testing
Safer Sex
Find a Date
Newly Diagnosed
HIV 101
Disclosing Your Status
Starting Treatment
Help Paying for Meds
Search for the Cure
POZ Stories
POZ Opinion
POZ Exclusives
Read the Blogs
Visit the Forums
Job Listings
Events Calendar
POZ on Twitter

Ask POZ Pharmacist

Talk to Us
Has a pet helped you deal with your HIV?


more surveys
Contact Us
We welcome your comments!
[ about Smart + Strong | about POZ | POZ advisory board | partner links | advertising policy | advertise/contact us | site map]
© 2016 Smart + Strong. All Rights Reserved. Terms of use and Your privacy.
Smart + Strong® is a registered trademark of CDM Publishing, LLC.